Form 4: Takeda Executive Reports RSU Award

Rhonda Pacheco, President of Takeda's U.S. Business Unit, received an award of 50,156 Restricted Stock Units (RSUs) on July 1, 2026.

Summary

• Rhonda Janice Pacheco, President of Takeda Pharmaceutical Co. Ltd.'s U.S. Business Unit, was granted 50,156 American Depositary Shares (ADS) in the form of Restricted Stock Units (RSUs) on July 1, 2026.
• These RSUs represent a contingent right to receive one ADS each.
• The RSUs are scheduled to vest in three equal annual installments, commencing on July 1, 2027.
• Following this award, Ms. Pacheco beneficially owns 199,408 ADSs directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard executive compensation event (RSU award) without immediate financial performance indicators or significant strategic shifts.

Positives

• Award of 50,156 Restricted Stock Units (RSUs) to a key executive, indicating continued investment in leadership and potential future value.
• The RSU award is structured for vesting over three years, suggesting a retention incentive for the executive.

Risks

• The value of the RSUs is contingent on the future performance and stock price of Takeda Pharmaceutical Co. Ltd.
• Vesting is subject to continued employment and other conditions as per the award agreement.

Future Outlook

The RSUs vest in three equal annual installments beginning on July 1, 2027, indicating a future potential increase in Ms. Pacheco's beneficial ownership.

Industry Context

StockSavvy.ai notes that RSU awards are a common form of executive compensation in the pharmaceutical industry, used to align management interests with long-term shareholder value and to retain key talent.

Stakeholder Impact

• Shareholders: The RSU award represents potential future dilution if all RSUs are exercised, but also signals executive commitment and alignment with company performance.
• Employees: May reflect standard compensation practices within the company.
• Management: Reinforces the compensation structure for key executives.

Next Steps

• Vesting of RSUs in three equal annual installments starting July 1, 2027.
• Continued monitoring of Takeda Pharmaceutical Co. Ltd.'s performance and executive compensation practices.

Key Dates

Keywords

Form 4, SEC Filing, Takeda Pharmaceutical, Rhonda Pacheco, Restricted Stock Units, RSU Award, Executive Compensation, Insider Trading, Beneficial Ownership, Stock Options